Loading clinical trials...
Loading clinical trials...
A Tissue Collection Study to Explore the Correlation Between ATM Genetic Alterations by Next-Generation Sequencing and ATM Loss-of-Protein Via IHC (ATR-ID Study)
Conditions
Interventions
Determination of ATM alteration status.
Locations
3
United States
Oklahoma University
Oklahoma City, Oklahoma, United States
Tennessee Oncology
Nashville, Tennessee, United States
Sarah Cannon Research UK
London, United Kingdom
Start Date
May 28, 2021
Primary Completion Date
June 30, 2022
Completion Date
June 30, 2022
Last Updated
August 1, 2022
NCT04643418
NCT06911333
NCT06883539
NCT06895681
Lead Sponsor
Artios Pharma Ltd
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions